Immunosympathectomy as the first phenotypic knockout with antibodies

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 13, 2013, Pages 4877-4885

  Cattaneo, Antonino ^a,b  

^a SCUOLA NORMALE SUPERIORE   (Italy)

^b EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

Author keywords

Anti NGF antibodies; Intrabodies; Protein interference; Protein knockout

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; NERVE GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE A; RABBIT ANTISERUM; RANIBIZUMAB; RECOMBINANT ANTIBODY; SNAKE VENOM; TANEZUMAB; TRASTUZUMAB; VASCULOTROPIN ANTIBODY;

ACCURACY; ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANTIANGIOGENIC ACTIVITY; ANTIBODY SPECIFICITY; CANCER GROWTH; CELL SUBPOPULATION; CHEMICAL SYMPATHECTOMY; CHRONIC PAIN; DRUG EFFECT; DRUG EFFICACY; DRUG SPECIFICITY; EXUDATIVE MACULAR DEGENERATION; GENE INACTIVATION; GENE SILENCING; GENE TARGETING; HUMAN; IMMUNOSYMPATHECTOMY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; NERVE CELL; NERVE FIBER GROWTH; NONHUMAN; OSTEOARTHRITIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PURIFICATION; REVIEW; RNA INTERFERENCE; SALIVARY GLAND; SARCOMA; SYMPATHETIC NERVE CELL; TUMOR ABLATION;

EID: 84875551664     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1217586110     Document Type: Review

References (67)

1. Levi-Montalcini R (2000) Cantico di Una Vita (Raffaello Cortina, Milano).
2. Levi-Montalcini R, Booker B (1960) Destruction of the sympathetic ganglia in mammals by an antiserum to a nerve-growth protein. Proc Natl Acad Sci USA 46(3):384-391.
3. Cohen S (1960) Purification of a nerve-growth promoting protein from the mouse salivary gland and its neuro-cytotoxic antiserum. Proc Natl Acad Sci USA 46(3):302-311.
4. Levi-Montalcini R, Booker B (1960) Excessive growth of the sympathetic ganglia evoked by a protein isolated from mouse salivary glands. Proc Natl Acad Sci USA 46(3):373-384.
5. Cohen S, Levi-Montalcini R (1956) A nerve growth-stimulating factor isolated from snake venom. Proc Natl Acad Sci USA 42(9): 571-574.
6. Levi-Montalcini R, Cohen S (1956) In vitro and in vivo effects of a nerve growth-stimulating agent isolated from snake venom. Proc Natl Acad Sci USA 42(9):695-699.
7. Levi-Montalcini R (1952) Effects of mouse tumor transplantation on the nervous system. Ann N Y Acad Sci 55(2):330-344.
8. Levi-Montalcini R, Meyer H, Hamburger V (1954) In vitro experiments on the effects of mouse sarcomas 180 and 37 on the spinal and sympathetic ganglia of the chick embryo. Cancer Res 14 (1):49-57.
9. Cohen S, Levi-Montalcini R, Hamburger V (1954) A nerve growthstimulating factor isolated from sarcom as 37 and 180. Proc Natl Acad Sci USA 40(10):1014-1018.
10. Levi-Montalcini R (1988) In Praise of Imperfection: My Life and Work (Sloan Foundation Science Series/Basic Books, New York).
11. Levi-Montalcini R (1958) Chemical stimulation of nerve growth. In McElroy WD and Glass B (eds.). A symposium on the chemical basis of development (Johns Hopkins Press, Baltimore) 646-664.
12. Levi-Montalcini R, Cohen S (1960) Effects of the extract of the mouse submaxillary salivary glands on the sympathetic system of mammals. Ann N Y Acad Sci 85:324-341.
13. Cohen S (1962) Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 237:1555-1562.
14. Levi-Montalcini R (1964) Growth control of nerve cells by a protein factor and its antiserum: Discovery of this factor may provide new leads to understanding of some neurogenetic processes. Science 143(3602):105-110.
15. Barde YA, Edgar D, Thoenen H (1982) Purification of a new neurotrophic factor from mammalian brain. EMBO J 1(5):549-553.
16. Conference on Immunology and Development (1956). Edds M V (Ed.) The University of Chicago Press.
17. Aloe L, Cozzari C, Calissano P, Levi-Montalcini R (1981) Somatic and behavioral postnatal effects of fetal injections of nerve growth factor antibodies in the rat. Nature 291(5814):413-415.
18. Carroll SL, et al. (1992) Dorsal root ganglion neurons expressing trk are selectively sensitive to NGF deprivation in utero. Neuron 9(4): 779-788.
19. Johnson EM, Jr., Gorin PD, Brandeis LD, Pearson J (1980) Dorsal root ganglion neurons are destroyed by exposure in utero to maternal antibody to nerve growth factor. Science 210(4472):916-918.
20. Ruit KG, Elliott JL, Osborne PA, Yan Q, Snider WD (1992) Selective dependence of mammalian dorsal root ganglion neurons on nerve growth factor during embryonic development. Neuron 8(3): 573-587.
21. Frade JM, Rodríguez-Tébar A, Barde YA (1996) Induction of cell death by endogenous nerve growth factor through its p75 receptor. Nature 383(6596):166-168.
22. Berardi N, et al. (1994) Monoclonal antibodies to nerve growth factor affect the postnatal development of the visual system. Proc Natl Acad Sci USA 91(2):684-688.
23. Capecchi MR (1989) Altering the genome by homologous recombination. Science 244(4910):1288-1292.
24. Snider WD (1994) Functions of the neurotrophins during nervous system development: What the knockouts are teaching us. Cell 77(5): 627-638.
25. Crowley C, et al. (1994) Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell 76(6):1001-1011.
26. Smeyne RJ, et al. (1994) Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature 368(6468):246-249.
27. Pearson J, Johnson EM, Brandeis L (1983) Effects of antibodies to nerve growth factor on intrauterine development of derivatives of cranial neural crest and placode in the guinea pig. Dev Biol 96(1): 32-36.
28. Levi-Montalcini R, Angeletti PU (1966) Second symposium on catecholamines. Modification of sympathetic function. Immunosympathectomy. Pharmacol Rev 18(1):619-628.
29. Craig AD (2002) How do you feel? Interoception: The sense of the physiological condition of the body. Nat Rev Neurosci 3(8): 655-666.
30. Craig AD (2009) How do you feel-now? The anterior insula and human awareness. Nat Rev Neurosci 10(1):59-70.
31. Indo Y (2012) Nerve growth factor and the physiology of pain: Lessons from congenital insensitivity to pain with anhidrosis. Clin Genet 82(4):341-350.
32. Indo Y (2009) Nerve growth factor, interoception, and sympathetic neuron: Lesson from congenital insensitivity to pain with anhidrosis. Auton Neurosci 147(1-2):3-8.
33. Einarsdottir E, et al. (2004) A mutation in the nerve growth factor beta gene (NGFB) causes loss of pain perception. Hum Mol Genet 13(8):799-805.
34. Capsoni S, et al. (2011) Taking pain out of NGF: A "painless" NGF mutant, linked to hereditary sensory autonomic neuropathy type V, with full neurotrophic activity. PLoS ONE 6(2):e17321.
35. Pezet S, McMahon SB (2006) Neurotrophins: Mediators and modulators of pain. Annu Rev Neurosci 29:507-538.
36. Lane NE, et al. (2010) Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 363(16):1521-1531.
37. Wood JN (2010) Nerve growth factor and pain. N Engl J Med 363(16):1572-1573.
38. Covaceuszach S, et al. (2012) Single cycle structure-based humanization of an anti-nerve growth factor therapeutic antibody. PLoS ONE 7(3):e32212.
39. Ugolini G, Marinelli S, Covaceuszach S, Cattaneo A, Pavone F (2007) The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proc Natl Acad Sci USA 104(8): 2985-2990.
40. Holmes D (2012) Anti-NGF painkillers back on track? Nat Rev Drug Discov 11(5):337-338.
41. Ferrara N (2010) Vascular endothelial growth factor and agerelated macular degeneration: From basic science to therapy. Nat Med 16(10):1107-1111.
42. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391-400.
43. Winter G, Milstein C (1991) Man-made antibodies. Nature 349(6307):293-299.
44. Cattaneo A, Biocca S (1997) Intracellular Antibodies: Developments and Applications (Landes Biosciences, Springer, Austin).
45. Cattaneo A, Neuberger MS (1987) Polymeric immunoglobulin M is secreted by transfectants of non-lymphoid cells in the absence of immunoglobulin J chain. EMBO J 6(9):2753-2758.
46. Piccioli P, et al. (1995) Neuroantibodies: Ectopic expression of a recombinant anti-substance P antibody in the central nervous system of transgenic mice. Neuron 15(2):373-384.
47. Capsoni S, Brandi R, Arisi I, D'Onofrio M, Cattaneo A (2011) A dual mechanism linking NGF/proNGF imbalance and early inflammation to Alzheimer's disease neurodegeneration in the AD11 anti-NGF mouse model. CNS Neurol Disord Drug Targets 10(5):635-647.
48. Capsoni S, et al. (2000) Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci USA 97(12):6826-6831.
49. Capsoni S, Tiveron C, Vignone D, Amato G, Cattaneo A (2010) Dissecting the involvement of tropomyosin-related kinase A and p75 neurotrophin receptor signaling in NGF deficit-induced neurodegeneration. Proc Natl Acad Sci USA 107(27):12299-12304.
50. Heppner FL, et al. (2001) Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294(5540):178-182.
51. Biocca S, Cattaneo A (1995) Intracellular immunization: Antibody targeting to subcellular compartments. Trends Cell Biol 5(6):248-252.
52. Biocca S, Neuberger MS, Cattaneo A (1990) Expression and targeting of intracellular antibodies in mammalian cells. EMBO J 9(1): 101-108.
53. Biocca S, Pierandrei-Amaldi P, Campioni N, Cattaneo A (1994) Intracellular immunization with cytosolic recombinant antibodies. Biotechnology (N Y) 12(4):396-399.
54. Marasco WA, Haseltine WA, Chen SY (1993) Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci USA 90 (16):7889-7893.
55. Tavladoraki P, et al. (1993) Transgenic plants expressing a functional single-chain Fv antibody are specifically protected from virus attack. Nature 366(6454):469-472.
56. Lo AS, Zhu Q, Marasco WA (2008) Intracellular antibodies (intrabodies) and their therapeutic potential. Handb Exp Pharmacol (181):343-373.
57. Lobato MN, Rabbitts TH (2003) Intracellular antibodies and challenges facing their use as therapeutic agents. Trends Mol Med 9(9):390-396.
58. Miller TW, Messer A (2005) Intrabody applications in neurological disorders: Progress and future prospects. Mol Ther 12(3):394-401.
59. Tanaka T, Williams RL, Rabbitts TH (2007) Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. EMBO J 26(13):3250-3259.
60. Visintin M, Tse E, Axelson H, Rabbitts TH, Cattaneo A (1999) Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc Natl Acad Sci USA 96(21):11723-11728.
61. Meli G, Visintin M, Cannistraci I, Cattaneo A (2009) Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers. J Mol Biol 387(3): 584-606.
62. Tanaka T, Rabbitts TH (2010) Protocol for the selection of singledomain antibody fragments by third generation intracellular antibody capture. Nat Protoc 5(1):67-92.
63. Visintin M, Meli GA, Cannistraci I, Cattaneo A (2004) Intracellular antibodies for proteomics. J Immunol Methods 290(1-2):135-153.
64. Tse E, Rabbitts TH (2000) Intracellular antibody-caspase-mediated cell killing: An approach for application in cancer therapy. Proc Natl Acad Sci USA 97(22):12266-12271.
65. Melchionna T, Cattaneo A (2007) A protein silencing switch by ligand-induced proteasome-targeting intrabodies. J Mol Biol 374(3): 641-654.
66. Ratto MH, et al. (2012) The nerve of ovulation-inducing factor in semen. Proc Natl Acad Sci USA 109(37):15042-15047.
67. Chao MV (2010) A conversation with Rita Levi-Montalcini. Annu Rev Physiol 72:1-13.